Related Experiment Video
Updated: Jun 28, 2026

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
Published on: October 2, 2017
BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Jinxiu Li1, Mary L Nelson1, Li Li1
1University of Utah Salt Lake City, UT United States.
Abstract:
Synovial sarcoma (SyS) incorporates the SS18::SSX fusion oncoprotein into GLTSCR1-containing BRG1/BRM and associated factors (GBAF) complexes, which confers a dependency on the GBAF subunit BRD9. However, SyS clinical trials with multiple BRD9 degraders failed to achieve clinically impactful remissions. Here, we identified a mechanistic framework to explain these results. BRD9 depletion served to blunt proliferation in SyS harboring minimal genomic alterations, rare in trial participants. In cultured cells, xenografts, and recombinant purified complexes, BRD9 loss did not impact GBAF assembly. Although BRD9 degradation in SyS reduced GBAF enrichment at target loci, BRD9-less complexes maintained or increased chromatin accessibility and associated gene transcription. Biochemical assays with purified recombinant GBAF demonstrated increased nucleosome sliding in the absence of BRD9. Together, these findings show that BRD9 restrains GBAF activity, with BRD9 degradation increasing enzymatic remodeling and target gene expression by fusion oncoprotein-distributed GBAFs in SyS. This subtle epigenetic disturbance creates a low hurdle for SyS to surpass, limiting the therapeutic efficacy of BRD9 degraders.
Insights
Synovial sarcoma cells depend on BRD9, but its depletion paradoxically boosts cancer gene activity. This explains why BRD9 degraders failed in clinical trials for synovial sarcoma (SyS).
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- Synovial sarcoma (SyS) relies on the SS18::SSX oncoprotein within GBAF complexes, creating a dependency on the BRD9 subunit.
- Clinical trials using BRD9 degraders for SyS have not yielded significant clinical benefits.
Purpose of the Study:
- To elucidate the mechanistic basis for the limited efficacy of BRD9 degraders in synovial sarcoma.
- To understand the role of BRD9 in GBAF complex function and its impact on SyS pathogenesis.
Main Methods:
- Cellular and xenograft models of SyS
- Biochemical assays with purified GBAF complexes
- Analysis of GBAF enrichment, chromatin accessibility, and gene transcription upon BRD9 depletion
Main Results:
- BRD9 depletion did not disrupt GBAF complex assembly but reduced its enrichment at target loci.
- In the absence of BRD9, GBAF complexes maintained or increased chromatin accessibility and gene transcription.
- Biochemical assays revealed that BRD9 restrains GBAF's nucleosome sliding activity, and its degradation enhances this remodeling.
Conclusions:
- BRD9 acts as a brake on GBAF enzymatic activity; its degradation unleashes increased chromatin remodeling and gene expression in SyS.
- This enhanced epigenetic activity presents a low-level challenge for SyS, explaining the limited therapeutic success of BRD9 degraders.
Related Concept Videos
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
TGF - β Signaling Pathway
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Restarting Stalled Replication Forks
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...